Sequential changes in gene expression profiles in breast cancers during treatment with the aromatase inhibitor, letrozole

The study aim was to identify early (within 14 days) and late changes (by 3 months) in breast cancer gene expression profiles associated with neoadjuvant therapy with letrozole. RNA from sequential tumour biopsies in 54 patients was analyzed on microarrays; changes were determined by frequency, magnitude and significance analyses. Substantially more genes were changed at 3 months (1503) than at 14 days (237). Early changed genes were associated with cell cycle (downregulation), blood vessel development and extracellular matrix (upregulation); late changes included ‘cellular metabolic process’, ‘generation of precursor metabolites and energy’ (decreased) and ‘cell adhesion’ ‘biological adhesion‘ (increased). A striking difference between the early and late changes was the general location of downregulated genes—nuclear structures at 14 days and mitochondria after 3 months. These changes in gene expression profiles provide a new and important database by which to understand molecular mechanisms of letrozole in breast cancers.

[1]  C. Boni,et al.  Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[2]  J. Dixon,et al.  Local endocrine effects of aromatase inhibitors within the breast , 2001, The Journal of Steroid Biochemistry and Molecular Biology.

[3]  M. Ellis,et al.  Preoperative treatment of postmenopausal breast cancer patients with letrozole: A randomized double-blind multicenter study. , 2001, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  P. Lønning,et al.  Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  R. Prescott,et al.  MIB-1 assessments in breast cancers. , 2002, Breast.

[6]  A. Scherer,et al.  Optimized protocol for linear RNA amplification and application to gene expression profiling of human renal biopsies. , 2003, BioTechniques.

[7]  W. Miller.  Aromatase inhibitors: mechanism of action and role in the treatment of breast cancer. , 2003, Seminars in oncology.

[8]  Rafael A Irizarry,et al.  Exploration, normalization, and summaries of high density oligonucleotide array probe level data. , 2003, Biostatistics.

[9]  E. Perez,et al.  A Randomized Trial of Letrozole in Postmenopausal Women after Five Years of Tamoxifen Therapy for Early-Stage Breast Cancer , 2003 .

[10]  A. Howell,et al.  An open randomised trial of second-line endocrine therapy in advanced breast cancer: comparison of the Aromatase inhibitors letrozole and anastrozole. , 2004, European journal of cancer.

[11]  Alok J. Saldanha,et al.  Java Treeview - extensible visualization of microarray data , 2004, Bioinform..

[12]  Gordon K Smyth,et al.  Statistical Applications in Genetics and Molecular Biology Linear Models and Empirical Bayes Methods for Assessing Differential Expression in Microarray Experiments , 2011 .

[13]  Satoru Miyano,et al.  Open source clustering software , 2004 .

[14]  Gordon K. Smyth,et al.  limma: Linear Models for Microarray Data , 2005 .

[15]  Rafael A. Irizarry,et al.  Bioinformatics and Computational Biology Solutions using R and Bioconductor , 2005 .

[16]  W. Miller,et al.  Proliferation, steroid receptors and clinical/pathological response in breast cancer treated with letrozole , 2006, British Journal of Cancer.

[17]  G. Hampton,et al.  Changes in breast cancer transcriptional profiles after treatment with the aromatase inhibitor, letrozole , 2007, Pharmacogenetics and genomics.

[18]  Qi Zheng,et al.  GOEAST: a web-based software toolkit for Gene Ontology enrichment analysis , 2008, Nucleic Acids Res..

[19]  T. Sing,et al.  Gene expression profiles differentiating between breast cancers clinically responsive or resistant to letrozole. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  Audrey Kauffmann,et al.  Bioinformatics Applications Note Arrayqualitymetrics—a Bioconductor Package for Quality Assessment of Microarray Data , 2022 .

[21]  W. Miller,et al.  Genes Discriminating between Breast Cancers Responsive or Resistant to the Aromatase Inhibitor, Letrozole , 2010 .